Maresin 1通过miR-21改善类风湿关节炎中Treg/Th17失衡
研究纳入类风湿关节炎(RA)患者和健康对照,构建胶原诱导性关节炎(CIA)模型,发现MaR1在非活动性RA患者中较高、活动性RA中较低,FoxP3/RORc比值与疾病活动度评分28呈负相关;MaR1干预CIA模型可减轻关节炎症和损伤、改善Treg/Th17失衡,机制涉及miR-21上调调节Treg/Th17平衡。
要点
- MaR1浓度在非活动性RA患者中高于对照、在活动性RA患者中低于对照。
- FoxP3/RORc比值与DAS28呈负相关。
- MaR1干预CIA模型减轻关节炎症和损伤并改善Treg/Th17比值。
核心结论
- MaR1是RA的治疗靶点,可能通过影响疾病中失衡的Treg/Th17比值发挥作用。
研究设计与样本
- 研究纳入RA患者和健康对照,构建胶原诱导性关节炎(CIA)模型检测临床评分、组织病理学变化和Treg/Th17比值,并用纯化初始CD4+ T细胞研究MaR1对分化过程的影响及microRNA微阵列研究下游microRNA。
主要发现
- 与对照相比,MaR1浓度在非活动性RA患者中较高、在活动性RA患者中较低。
- Treg转录因子FoxP3在非活动性RA中表达最高、在活动性RA中表达最低,而Th17转录因子RORc呈相反趋势。
- FoxP3/RORc比值与疾病活动度评分28呈负相关。
- MaR1干预CIA模型减轻关节炎症和损伤,并改善失衡的Treg/Th17比值。
- 在特定分化条件下,MaR1增加Treg细胞比例而降低Th17细胞比例;miR-21被证实为MaR1下游microRNA,被MaR1上调,调节Treg/Th17平衡从而改善RA进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treg/Th17 imbalance plays an important role in rheumatoid arthritis (RA). Maresin 1 (MaR1) prompts inflammation resolution and regulates immune responses. We explored the effect of MaR1 on RA progression and investigated the correlation between MaR1 and Treg/Th17 balance. METHODS: Both patients with RA and healthy controls were recruited into the study. Collagen-induced arthritis (CIA) model was constructed to detect the clinical score, histopathological changes and Treg/Th17 ratio. Purified naive CD4+ T-cells were used to study the effect of MaR1 on its differentiation process and microRNA microarray studies were performed to investigate MaR1 downstream microRNAs in this process. MicroRNA transfection experiments were conducted by lentivirus to verify the mechanism of MaR1 on Treg/Th17 balance. RESULTS: Compared with controls, the MaR1 concentration was higher in the patients with inactive RA and lower in the patients with active RA. Expression of the Treg transcription factor FoxP3 was the highest in inactive RA and the lowest in active RA, while the Th17 transcription factor RORc showed a reverse trend. An inverse correlation was observed between the FoxP3/RORc ratio and Disease Activity Score 28. Intervention of MaR1 in the CIA model reduced joint inflammation and damage, and improved the imbalanced Treg/Th17 ratio. MaR1 increased Treg cells proportion while reduced Th17 cells proportion under specific differentiation conditions. Furthermore, miR-21 was verified as MaR1 downstream microRNA, which was upregulated by MaR1, modulating the Treg/Th17 balance and thus ameliorating the RA progression. CONCLUSIONS: MaR1 is a therapeutic target for RA, likely operating through effects on the imbalanced Treg/Th17 ratio found in the disease.
引用
- Jin S, Chen H, Li Y, et al. Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21. Ann Rheum Dis. 2018. PMID: 30045854. doi:10.1136/annrheumdis-2018-213511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。